DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting Apr 30, 2019 04:58PM
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease Feb 14, 2019 08:00AM
DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders Jan 22, 2019 07:45AM
UPDATE -- DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease Jan 3, 2019 10:41AM
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease Jan 3, 2019 07:30AM


Nov 12, 2018 04:45PM DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
Nov 6, 2018 05:00PM DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
Sep 27, 2018 08:52AM DiaMedica Therapeutics and Ahon Pharma, a Fosun Pharma Portfolio Company, Announces Signing of License Agreement for DM199 in China for Acute Ischemic Stroke
Sep 5, 2018 08:00AM DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
Aug 23, 2018 07:30PM DiaMedica Issues Stock Option Grant
May 3, 2018 08:30AM DiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Trial in Patients with Chronic Kidney Disease
Apr 17, 2018 09:00PM DiaMedica Issues Stock Option Grants
Apr 5, 2018 07:15AM DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer
Mar 29, 2018 06:08PM DiaMedica Therapeutics Announces Final Closing of Private Placement
Mar 20, 2018 05:40PM DiaMedica Therapeutics Announces Closing of Private Placement
Feb 22, 2018 07:00AM DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke
Jan 29, 2018 08:45AM DiaMedica to Present at the 14th Annual Noble Investor Conference
Jan 18, 2018 08:00AM DiaMedica Letter to Shareholders
Nov 22, 2017 08:00AM DiaMedica Therapeutics Announces Ethics Committee Clearance at First Site to Initiate REMEDY Phase 2 Trial for Acute Ischemic Stroke
Nov 7, 2017 08:00AM DiaMedica Therapeutics Announces Publication of Positive Clinical Results for DM199 in the International Journal of Clinical Trials
Oct 31, 2017 11:24AM DiaMedica Announces Dr. Robert Stanton as Scientific Advisor for Upcoming Chronic Kidney Disease Trials
May 1, 2017 08:34AM DiaMedica Announces Recently Granted Formulation Patent in U.S. for DM199
Apr 25, 2017 08:00AM DiaMedica Announces Dr. Nancy Chang to its Strategic Advisory Board
Apr 18, 2017 08:00AM DiaMedica Therapeutics Completes Private Placement With U.S. Based Family Office
Mar 20, 2017 08:00AM DiaMedica Announces Issuance of European Composition of Matter Patent and Additional Worldwide Filings for DM199
Mar 17, 2017 05:00PM DiaMedica Issues Stock Option Grant
Mar 13, 2017 08:00AM DiaMedica Presents Updated Positive DM199 Phase Ib Trial Identifying A Superior Subcutaneous Delivery Profile
Dec 23, 2016 05:53PM DiaMedica Announces Name Change to DiaMedica Therapeutics Inc.